Regeneron, a biotech company, will acquire 23andMe for $256 million and vowed to comply with the genetic testing company's ...

Regeneron Pharmaceuticals will acquire embattled DNA testing company 23andMe in a $256 million court-supervised sale, ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection. In March, 23andMe said ...

Regeneron announced a plan to acquire genetic testing firm 23andMe through bankruptcy court, including access to personal genetic data. What to know ...

Under the proposed agreement with Regeneron, the Tarrytown, New York, drugmaker will acquire 23andMe's assets, including its personal genome service and total health and research services.

Hudson Valley company. Tarrytown based Regeneron Pharmaceuticals, Inc. announced on Monday that it has been named the successful bidder in the bankruptcy auction for substantially all of the assets of ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing ...

The sale was for $256 million and is expected to be complete by the third quarter of this year, according to a Regeneron news ...

Genetic testing firm 23andMe is set to be acquired by drug company Regeneron Pharmaceuticals following its bankruptcy in March, the companies announced on Monday, May 19. Regeneron purchased the ...

Regeneron Pharmaceuticals said Monday it had ... The deal is subject to bankruptcy court and regulatory approvals. The Tarrytown, N.Y.-based biotech said it would continue 23andMe’s consumer ...